Gold Nanoparticles - Active Enrollment

We are conducting a trial for utilizing gold nanoparticles paired with infrared laser heat. Eligible patients have to have superficial tumors. We are treating the following types:

• Dogs with large mast cell tumors (>2 cm)

• Dogs with soft tissue sarcomas (<2cm in diameter)

• Dogs with oral melanoma (2-3cm diameter)

• Dogs with cutaneous or footpad melanoma (<2cm)

• Cats with oral squamous cell carcinoma not involving the bone

• Cats with other cutaneous tumors like Mast cell tumors, Sarcomas or Carcinomas

This clinical trial utilizes gold nanoparticles in a gross disease setting.

Gold Nanoparticles are inert and are given IV to the patient and after a period of time the patient comes back to have the tumor heated with a laser. As the tumor vasculature is heated through the external near infrared spectrum of light, the gold nanoparticles are excited, the laser energy is converted to heat and the tumor vasculature is disrupted killing the tumor from the inside out.

Smaller tumors typically need only the 1 session of heat but larger tumors may need more than 1 session of heat (average 2-3 for sarcomas).

THE TRIAL IS NOW ENROLLING PATIENTS!

If you have a potential case to discuss, have a patient with a tumor in a bad location for surgery or if you would like to learn more, please contact us at 425-697-2272 for more information.

Gilvetmab paired with EGFR for Histo diagnosed Hemangiosarcoma - CLOSED

The current clinical trial for EGFR vaccination with Yale has been granted the rights to add Gilvetmab for these patients through a MERCK Product Grant Support. These patients received Gilvetmab paired with Carboplatin and EGFR. We will now be looking at dogs with Carboplatin and EGFR as the comparison arm.

 Paclitaxel for K9 Hemangiosarcoma - CLOSED

BARC was enrolling patients in a clinical trial for a unique chemotherapy agent for splenic hemangiosarcoma patients but we have reached the enrollment goal and the trial is now closed. The company that produces Paclitaxel will be evaluating the results in hopes to bring the drug to market.

Trial Status: CLOSED FOR DATA REVIEW

Paclitaxel for Feline Tumors - CLOSED

BARC was enrolling Feline patients in a clinical trial for Paclitaxel in a variety of tumor types. The company that produces Paclitaxel will be evaluating the results in hopes to bring the drug to market.

Trial Status: CLOSED FOR DATA REVIEW

Study for Canine Lymphoma - CLOSED

We just completed the enrollment for this novel immunotherapy in dogs with Naive B cell lymphoma or Refractory B cell lymphoma. Once the dose finding data has been evaluated we are hopeful a second arm of the trial may be available for patients with B cell lymphoma to look at efficacy.

Financial Support: Fully funded. All treatments and procedures associated with the clinical trial will occur with no cost to the owner.

Trial Status: CLOSED FOR DATA REVIEW

TLR 7,8,9 Immunotherapy - Coming soon

BARC is going to be enrolling patients in a clinical trial for a unique immunotherapy for gross disease sarcomas and carcinomas. We anticipate this trial being open in September 2026.

Trial Status: COMING SOON

 Randomized trial of Fecal Transplant with Palladia for multiple tumor types - COMING SOON

We will be looking at whether receiving fecal transplant capsules at the same time as Palladia can improve the microbiome in dogs and potentially reduce the side effect profile of Palladia. Dogs receiving Palladia naively will enroll to receive fecal transplant capsules or placebo but active Palladia. The first 3 months of the Palladia administration, additional samples will be collected from the patient to determine how the microbiome adjusts during this timeframe.

Trial Status: COMING SOON

Study for Canine Superficial Squamous Cell Carcinoma (SCC) - Active Enrollment

We are enrolling pet companion dogs that have been diagnosed with non-metastatic squamous cell carcinoma (SCC, a type of cancer) in a clinical trial for a newly formulated chemotherapy treatment delivered via an intratumor injection. An intratumor injection requires a much lower dose of carboplatin than required by administration systemically. Additionally, this new formulation hopes to provide long-acting local activity.

Eligibility for Dogs to Participate in the Study include but are not limited to:

· The dog is diagnosed cytologically or histologically with Squamous cell carcinoma.

· The dog has at least one lesion with a longest diameter (LD) of ≥1.0 cm that can be measured to assess response to treatment.

· The dog has no evidence of metastasis based on thoracic radiographs and cytological evaluation of local lymph nodes, and any palpably enlarged lymph nodes.

· The dog has not received prior treatment with radiation, immunotherapy, or chemotherapy for cancer.

· The dog has no renal, cardiovascular, hepatic, and/or gastrointestinal dysfunction, neutropenia, or thrombocytopenia.

· The dog has no uncontrolled systemic disorders (such as diabetes mellitus) other than SCC.

· The dog has no significant co-morbid illness, which includes but is not limited to a history of congestive heart failure or clinical coagulopathy.

Financial Support: Fully funded. All treatments and procedures associated with the clinical trial will occur with no cost to the owner.

Trial Status: Currently Ongoing

EGFR Immunotherapy - Active Enrollment

BARC continues to offer a unique immunotherapy that targets the EGFR/HER2 pathway. Epidermal Growth Factor Receptor (EGFR) is overexpressed on a number of human cancers, and often is indicative of a poor outcome.

We are hoping to induce a polyclonal anti-EGFR/HER2 tumor antigen response by vaccine therapy.

We are enrolling companion dogs with spontaneous EGFR expressing tumors to receive a series of 2 vaccines 3 weeks apart. There is another visit after vaccination to draw a blood sample for antigen response analysis. Dogs with EGFR expressing tumors will be immunized with a short peptide of the EGFR extracellular domain with sequence homology to HER2.

To receive the immunotherapy without required Oncologist consultation:

1. Referral direct from another Veterinary Specialist (Oncologist, Internist, Surgeon, etc)

2. Viable tumor types include:

• Osteosarcoma patients

• Hemangiosarcoma patients

• Transitional Cell Carcinoma

• Pulmonary Carcinoma (with records review)

• High grade Mast cell tumors (with records review)

Naive patients can also schedule to have an Oncology consult and this therapy will be discussed if applicable to your dogs disease profile.

Please contact us today for more information!